Identification of novel polymorphisms in the 5’ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance
- 1 November 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 10 (8) , 695-704
- https://doi.org/10.1097/00008571-200011000-00004
Abstract
CYP1A2 activity has been demonstrated to be bimodally or trimodally distributed in several populations, consistent with a codominant or recessive functional genetic polymorphism. However, studies aimed at identifying polymorphisms in CYPIA2 have not yet adequately accounted for this distribution pattern. To search for functional polymorphisms, we performed genome-walking, polymerase chain reaction (PCR) sequencing, and cloning, and identified three novel polymorphisms in the 5' flanking region of CYP1A2: a T-3591G substitution, a G-3595T substitution, and a T-3605 insertion. The frequency of the T-3591G substitution was determined by a PCR-restriction fragment length polymorphism assay, and found to be significantly higher (P < 0.0001) in Taiwanese (allele frequency 0.128, n = 125) compared to Caucasians (0.017, n = 87) or African Americans (0.024, n = 104). The functional consequence of the T-3591G and the G-3595T substitutions was determined by site-directed mutagenesis followed by transient transfection experiments. The T-3591G mutation was shown to be nonfunctional, while although the G-3595T mutation appeared to result in an increase in promoter activity, this was only to a small degree and therefore unlikely to be important in vivo. In addition, we report 532 bases of 5' flanking sequence further upstream than that reported to date, and four sequence discrepancies compared to the original published sequence (G-3649C, deltaT-3650, deltaA-4072, and C-4093 ins).Keywords
This publication has 39 references indexed in Scilit:
- THE RELEVANCE OF ETHNIC INFLUENCES ON PHARMACOGENETICS TO THE TREATMENT OF PSYCHOSISDrug Metabolism and Drug Interactions, 2000
- Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese PopulationJapanese Journal of Cancer Research, 1999
- C/EBP and the Control of Phosphoenolpyruvate Carboxykinase Gene Transcription in the LiverPublished by Elsevier ,1998
- Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activityPharmacogenetics, 1995
- The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probesPharmacogenetics, 1994
- Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 micePharmacogenetics, 1993
- Fluvoxamine is a potent inhibitor of cytochrome P4501A2Biochemical Pharmacology, 1993
- Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolitesPharmacogenetics, 1992
- Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptivesEuropean Journal of Clinical Pharmacology, 1985
- The contribution of genetically determined oxidation status to inter‐ individual variation in phenacetin disposition.British Journal of Clinical Pharmacology, 1983